These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24507816)

  • 1. Erythropoiesis stimulating agents and other growth factors in low-risk MDS.
    Hellström-Lindberg E; van de Loosdrecht A
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):401-10. PubMed ID: 24507816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM.
    Kelaidi C; Beyne-Rauzy O; Braun T; Sapena R; Cougoul P; Adès L; Pillard F; Lamberto C; Charniot JC; Guerci A; Choufi B; Stamatoullas A; Slama B; De Renzis B; Ame S; Damaj G; Boyer F; Chaury MP; Legros L; Cheze S; Testu A; Gyan E; Béné MC; Rose C; Dreyfus F; Fenaux P
    Ann Hematol; 2013 May; 92(5):621-31. PubMed ID: 23358617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life.
    Hellström-Lindberg E; Gulbrandsen N; Lindberg G; Ahlgren T; Dahl IM; Dybedal I; Grimfors G; Hesse-Sundin E; Hjorth M; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Oberg G; Porwit-MacDonald A; Rådlund A; Samuelsson J; Tangen JM; Winquist I; Wisloff F;
    Br J Haematol; 2003 Mar; 120(6):1037-46. PubMed ID: 12648074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome.
    Jädersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit A; Cazzola M; Hellström-Lindberg E
    J Clin Oncol; 2008 Jul; 26(21):3607-13. PubMed ID: 18559873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
    Castelli R; Schiavon R; Rossi V; Deliliers GL
    Med Oncol; 2018 Apr; 35(5):76. PubMed ID: 29675620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
    Ljung T; Bäck R; Hellström-Lindberg E
    Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients.
    Bowen DT
    Semin Oncol; 2005 Aug; 32(4 Suppl 5):S16-23. PubMed ID: 16085013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar epoetin in elderly patients with low-risk myelodysplastic syndromes improves anemia, quality of life, and brain function.
    Castelli R; Deliliers GL; Colombo R; Moreo G; Gallipoli P; Pantaleo G
    Ann Hematol; 2014 Sep; 93(9):1523-9. PubMed ID: 24711171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group.
    Remacha AF; Arrizabalaga B; Villegas A; Manteiga R; Calvo T; Julià A; Fernández Fuertes I; González FA; Font L; Juncà J; del Arco A; Malcorra JJ; Equiza EP; de Mendiguren BP; Romero M
    Haematologica; 1999 Dec; 84(12):1058-64. PubMed ID: 10586205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.
    Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom AM; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hellström-Lindberg E
    Clin Cancer Res; 2005 Sep; 11(17):6291-9. PubMed ID: 16144933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supportive care, growth factors, and new therapies in myelodysplastic syndromes.
    Hellström-Lindberg E; Malcovati L
    Blood Rev; 2008 Mar; 22(2):75-91. PubMed ID: 18068281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model.
    Hellström-Lindberg E; Negrin R; Stein R; Krantz S; Lindberg G; Vardiman J; Ost A; Greenberg P
    Br J Haematol; 1997 Nov; 99(2):344-51. PubMed ID: 9375752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study.
    Mannone L; Gardin C; Quarre MC; Bernard JF; Vassilieff D; Ades L; Park S; Vaultier S; Hamza F; Beyne-rauzy MO; Cheze S; Giraudier S; Agape P; Legros L; Voillat L; Dreyfus F; Fenaux P;
    Br J Haematol; 2006 Jun; 133(5):513-9. PubMed ID: 16681638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life, physical function and MRI T2* in elderly low-risk MDS patients treated to a haemoglobin level of ≥120 g/L with darbepoetin alfa ± filgrastim or erythrocyte transfusions.
    Nilsson-Ehle H; Birgegård G; Samuelsson J; Antunovic P; Astermark J; Garelius H; Engström LM; Kjeldsen L; Nilsson L; Olsson A; Skov-Holm M; Wallvik J; Gulbrandsen N; Hellström-Lindberg E
    Eur J Haematol; 2011 Sep; 87(3):244-52. PubMed ID: 21623919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes.
    Mundle SD
    Future Oncol; 2007 Aug; 3(4):397-403. PubMed ID: 17661714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
    Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P
    Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin.
    Hellström-Lindberg E; Kanter-Lewensohn L; Ost A
    Leuk Res; 1997 May; 21(5):415-25. PubMed ID: 9225069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.